Monitor for Nasdaq listing approval and closing conditions. The CVRs provide optionality on Galera's legacy assets but are unlikely to generate material near-term value. The combined company's focus will be on Obsidian's lead candidate OBX-115, a TIL therapy for solid tumors. Post-merger, watch for clinical data readouts and cash runway updates.
Price Chart
Executive Summary
This S-4/A Amendment No. 3 registers shares of Gazelle Parent, Inc. common stock to be issued in connection with the reverse merger of Galera Therapeutics, Inc. (GRTX) and Obsidian Therapeutics, Inc. Galera stockholders will receive shares of the new parent company (expected to trade as OBX on Nasdaq) plus contingent value rights (CVRs) tied to legacy assets. A concurrent PIPE financing of $350 million will fund the combined company. Galera stockholders will own approximately 1.29% of the combined entity, while Obsidian securityholders and PIPE investors will own approximately 53.46% and 45.25%, respectively, based on illustrative assumptions. The merger is expected to close in Q3 2026.
Key Facts
- Galera stockholders will receive ~0.7515 shares of Parent common stock per Galera share (assuming a 1:200 reverse split), representing ~1.29% of the combined company.
- Obsidian securityholders will receive ~0.1375 shares of Parent common stock per Obsidian share, representing ~53.46% of the combined company.
- A concurrent PIPE financing of $350 million will be completed at closing, with PIPE investors receiving ~45.25% of the combined company.
- Galera stockholders will receive CVRs entitling them to 80% of net proceeds from tilarginine (5-year term) and 95% from the Supportive-Care Product Divestiture (10-year term).
- Parent common stock is expected to list on Nasdaq under the ticker OBX upon closing, currently expected in Q3 2026.
- Galera's board has approved the merger, and a majority of Galera stockholders have executed a written consent to adopt the merger agreement.
Financial Impact
Galera valued at $10M (assuming $(2.0)M net cash); Obsidian valued at $413.5M; combined company post-PIPE valued at ~$763.5M. Galera legacy stockholders diluted to ~1.29% ownership.
Risk Factors
- Merger may not close if Nasdaq listing or PIPE conditions are not satisfied.
- Galera stockholders face extreme dilution (~1.29% ownership) and CVRs may expire worthless.
- Combined company is pre-revenue and will require additional capital; going concern risk for Obsidian pre-merger.
- Regulatory and clinical risks for OBX-115 (TIL therapy) remain high.
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001193125-26-290449 |
| Document: d117787dex106.htm | 0001193125-26-290449 |
| Document: d117787dex107.htm | 0001193125-26-290449 |
| Document: d117787dex51.htm | 0001193125-26-290449 |
| Document: d117787dex81.htm | 0001193125-26-290449 |
| Document: d117787dex231.htm | 0001193125-26-290449 |
| Document: d117787dex232.htm | 0001193125-26-290449 |
| Document: 0001193125-26-290449-index-headers.html | 0001193125-26-290449 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 22d ago | SC 13G | $13.22 | awaiting T+20 | — | $14.25 (+7.79%) |
Sep 10, 2026 6w ago | EFFECT | $17.16 $12.24 | ▼ −28.67% | ▼ −30.80% | $14.25 (−16.96%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.25 (−58.09%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.25 (−58.09%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.25 (−58.09%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.25 (−58.09%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.25 (−58.09%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.25 (−58.09%) |
Aug 3, 2026 12w ago | 8-K | $34.00 $17.04 | ▲ +49.88% | ▲ +48.64% | $14.25 (+58.09%) |
Jul 6, 2026 16w ago | EFFECT | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers